Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults w...
Will the increased employee base and associated equity compensation affect the company's operating expense forecasts for the upcoming quarters?
What is the potential impact of this equity grant on the company's current valuation multiples (e.g., P/E, EV/EBITDA) and analyst coverage?
Is there any indication that the grant could trigger additional secondary offerings or affect the company's capital raising plans under Nasdaq Rule 5635(c)(4)?
9 days ago